Literature DB >> 7646824

Ocular adverse effects of neuropsychiatric agents. Incidence and management.

T Oshika1.   

Abstract

Neuropsychiatric agents may adversely affect the eye in various ways. The more frequently encountered effects include corneal oedema and pigmentary changes in the lens and cornea which are induced by phenothiazine derivatives; thioridazine-induced retinopathy; tricyclic antidepressant-induced accommodation interference and glaucoma; and lithium carbonate-induced exophthalmos and papilloedema. Several adverse effects, such as corneal oedema, retinopathy and glaucoma, are vision-threatening, and patients often fail to describe their symptoms properly. A more precise understanding of these conditions is essential for prompt diagnosis and appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646824     DOI: 10.2165/00002018-199512040-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  74 in total

1.  RETINAL PIGMENTATION IN A PATIENT RECEIVING THIORIDAZINE.

Authors:  A W SCOTT
Journal:  Arch Ophthalmol       Date:  1963-12

2.  Long term evolution of the side-effect lens opacities induced by chlorpromazine prolonged therapy.

Authors:  J B Baron; Y Rivoalan; P Morel
Journal:  Agressologie       Date:  1971

3.  [Optical atrophy and systemic damage: two cases of secondary reactions to phenothiazines in children].

Authors:  M T Bonaccorsi
Journal:  Laval Med       Date:  1967-01

4.  Asymmetric anterior segment changes induced by chlorpromazine.

Authors:  V P Deluise; J T Flynn
Journal:  Ann Ophthalmol       Date:  1981-08

5.  Ocular toxic changes associated with chlorpromazine and thioridazine.

Authors:  J R Siddall
Journal:  Can J Ophthalmol       Date:  1966-07       Impact factor: 1.882

6.  Clinical effects and treatment of imipramine and amitriptyline poisoning in children.

Authors:  C M Steel; J O'Duffy; S S Brown
Journal:  Br Med J       Date:  1967-09-09

7.  Eye and skin changes in psychiatric patients treated with chlorpromazine.

Authors:  M B Mathalone
Journal:  Br J Ophthalmol       Date:  1967-02       Impact factor: 4.638

8.  Chlorpromazine epithelial keratopathy.

Authors:  A W Johnson; W J Buffaloe
Journal:  Arch Ophthalmol       Date:  1966-11

9.  Lithium-induced downbeat nystagmus.

Authors:  D P Williams; B T Troost; J Rogers
Journal:  Arch Neurol       Date:  1988-09

10.  Welding arc maculopathy and fluphenazine.

Authors:  W J Power; S P Travers; D J Mooney
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

View more
  6 in total

Review 1.  Non-steroidal drug-induced glaucoma.

Authors:  M R Razeghinejad; M J Pro; L J Katz
Journal:  Eye (Lond)       Date:  2011-06-03       Impact factor: 3.775

2.  Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

Authors:  Fernando Caravaggio; Enzo Scifo; Etienne L Sibille; Sergio E Hernandez-Da Mota; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Exp Eye Res       Date:  2018-06-05       Impact factor: 3.467

Review 3.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

4.  Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis.

Authors:  Pantaleo Fornaro; Giovanni Calabria; Guido Corallo; Giovanni B Picotti
Journal:  Doc Ophthalmol       Date:  2002-07       Impact factor: 2.379

5.  Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder.

Authors:  Serkan Akkaya; Döndü M Ulusoy; Hatice Doğan; Mahmut E Arslan
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

6.  Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study.

Authors:  Pınar Bingöl-Kızıltunç; Esra Yürümez; Huban Atilla
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.